A pathologist’s primer on implementing new standard of care molecular biomarker testing for precision prostate cancer management

Online journal article in Molecular Pathology that offers 1.0 continuing education (CME) credit that can be used to fulfill CC Part II requirements.

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $5.00 or more

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

List the molecular markers that are most useful in the work-up of primary and metastatic prostatic adenocarcinoma.

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

List the molecular markers that are most useful in the work-up of primary and metastatic prostatic adenocarcinoma.

Outline a strategy for selecting or guiding the most appropriate specimen choice(s) for molecular biomarker testing in patients with prostatic adenocarcinoma.

Discuss the potential role of testing for mutations in mismatch repair genes (MMR) and in the homologous recombination repair (HRR) pathway-related genes in patients with prostatic adenocarcinoma.

View More View Less